CN104411308B - 通过给予某些合成化合物治疗阿尔茨海默病的方法 - Google Patents
通过给予某些合成化合物治疗阿尔茨海默病的方法 Download PDFInfo
- Publication number
- CN104411308B CN104411308B CN201380006684.XA CN201380006684A CN104411308B CN 104411308 B CN104411308 B CN 104411308B CN 201380006684 A CN201380006684 A CN 201380006684A CN 104411308 B CN104411308 B CN 104411308B
- Authority
- CN
- China
- Prior art keywords
- jkf
- alzheimer
- compound
- mice
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (3)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USPCT/US2012/022646 | 2012-01-26 | ||
PCT/US2012/022646 WO2012103282A2 (en) | 2011-01-26 | 2012-01-26 | Methods and compositions for treating alzheimer's disease |
PCT/IB2013/000458 WO2013111013A2 (en) | 2012-01-26 | 2013-01-25 | Methods for treating alzheimer's disease by administering certain synthetic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104411308A CN104411308A (zh) | 2015-03-11 |
CN104411308B true CN104411308B (zh) | 2016-09-28 |
Family
ID=48874665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380006684.XA Active CN104411308B (zh) | 2012-01-26 | 2013-01-25 | 通过给予某些合成化合物治疗阿尔茨海默病的方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104411308B (zh) |
WO (1) | WO2013111013A2 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101273962A (zh) * | 2007-11-22 | 2008-10-01 | 山东蓝金生物工程有限公司 | 含烷化剂的温控缓释注射剂及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2667896A4 (en) * | 2011-01-26 | 2015-04-01 | Cold Spring Harbor Lab | METHOD AND COMPOSITION FOR TREATING MORBUS ALZHEIMER |
-
2013
- 2013-01-25 WO PCT/IB2013/000458 patent/WO2013111013A2/en active Application Filing
- 2013-01-25 CN CN201380006684.XA patent/CN104411308B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101273962A (zh) * | 2007-11-22 | 2008-10-01 | 山东蓝金生物工程有限公司 | 含烷化剂的温控缓释注射剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2013111013A3 (en) | 2013-10-31 |
WO2013111013A8 (en) | 2014-08-07 |
CN104411308A (zh) | 2015-03-11 |
WO2013111013A2 (en) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mohamed et al. | The plasma membrane calcium ATPase 4 signalling in cardiac fibroblasts mediates cardiomyocyte hypertrophy | |
CN107530326A (zh) | 用于治疗病症的5ht激动剂 | |
CN104039960B (zh) | 用于治疗和诊断与五羟色胺‑、肾上腺素‑、去甲肾上腺素‑、谷氨酸‑和促肾上腺皮质素释放激素相关的病症的微rna和包含微rna的组合物 | |
JP2020524706A (ja) | 結節性硬化症複合体の処置におけるカンナビジオールの使用 | |
Shioda et al. | A novel cognitive enhancer, ZSET1446/ST101, promotes hippocampal neurogenesis and ameliorates depressive behavior in olfactory bulbectomized mice | |
Ma et al. | mTOR and tau phosphorylated proteins in the hippocampal tissue of rats with type 2 diabetes and Alzheimer's disease | |
Dong et al. | Protective effect of HIF-1α against hippocampal apoptosis and cognitive dysfunction in an experimental rat model of subarachnoid hemorrhage | |
US10676747B2 (en) | Methods for improving cognitive function via modulation of quinone reductase 2 | |
CN107427570A (zh) | 新型罗非鱼病毒及其用途 | |
AU2013348836B2 (en) | Learning and memory improver | |
Yan et al. | CSB6B prevents β-amyloid-associated neuroinflammation and cognitive impairments via inhibiting NF-κB and NLRP3 in microglia cells | |
Wattanathorn et al. | Mangifera indica fruit extract improves memory impairment, cholinergic dysfunction, and oxidative stress damage in animal model of mild cognitive impairment | |
CN107635566A (zh) | 治疗hbv感染的组合物和方法 | |
Fitz et al. | ABCA1 deficiency affects basal cognitive deficits and dendritic density in mice | |
CN107847551A (zh) | 具有抗病毒作用的肽和包含其的组合物 | |
Yang et al. | Role of endoplasmic reticulum stress in the loss of retinal ganglion cells in diabetic retinopathy | |
Ning et al. | Lycopene‐Loaded Microemulsion Regulates Neurogenesis in Rats with Aβ‐Induced Alzheimer’s Disease Rats Based on the Wnt/β‐catenin Pathway | |
Lin et al. | HDAC2 (Histone deacetylase 2): A critical factor in environmental enrichment‐mediated stroke recovery | |
CN104411308B (zh) | 通过给予某些合成化合物治疗阿尔茨海默病的方法 | |
CN101489542A (zh) | 清道夫受体类蛋白抑制剂在治疗传染性疾病中的应用 | |
CN103547289A (zh) | 治疗阿尔茨海默氏病的方法和组合物 | |
CN104203228A (zh) | 具有抗黄病毒的抗病毒活性的组合物 | |
CN108159423A (zh) | 治疗和预防心血管疾病的组合物和方法 | |
Chen et al. | Neural plasticity and addiction: integrin‐linked kinase and cocaine behavioral sensitization | |
CN108601772A (zh) | 用于治疗tdp-43蛋白质病的他克莫司 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Treatment of Alzheimer's disease by giving certain synthetic compounds Effective date of registration: 20210426 Granted publication date: 20160928 Pledgee: Zhongguancun Beijing technology financing Company limited by guarantee Pledgor: Bejing Joekai Biotechnology LLC Registration number: Y2021990000371 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220210 Granted publication date: 20160928 Pledgee: Zhongguancun Beijing technology financing Company limited by guarantee Pledgor: BEIJING JOEKAI BIOTECH. LLC Registration number: Y2021990000371 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |